Lupin Ltd.
LUPIN · NSE · Healthcare
With a 20% margin of safety, our buy-below price is ₹3,345.6.
Piotroski F-score 6/9 — quality of earnings & balance sheet.
Investability checklist
- ✓ROE above 15%26.9%
- ✓Low debt (D/E < 0.5)0.29x
- ✓Positive free cash flow
- ✓Revenue growth > 10%32%
- ✓Earnings growing89%
- ✓Net margin ≥ 10%19.1%
- ✓Current ratio > 1.51.90
- ✓Below our fair value
- ✓Margin of safety ≥ 20%
- ✓Above 200-day average
- ✕Above 50-day average
- –Positive 1-year return
- ✓Altman Z in safe zoneZ 5.53
- ✕Piotroski ≥ 76/9
1-year price
EOD · 2026-06-15Our scores
Key fundamentals
SWOT snapshot
Strengths
- •Strong return on equity (26.9%).
- •Lightly leveraged balance sheet.
- •Healthy profit margin (19.1%).
- •Financially solid — Altman Z 5.53.
Opportunities
- •Earnings growing (89% YoY).
- •Revenue growing (32% YoY).
- •Trading in our value buy zone versus sector peers.
- •Trades ~84% below our estimated fair value.
About Lupin Ltd.
Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India, the United States, and internationally. The company operates in two segments: Pharmaceuticals and Others. It engages in the drug discovery, development, production, marketing, and sale of various branded and generic formulations, biosimilars, over-the-counter and specialty drugs, and active pharmaceutical ingredients (APIs)
More in Healthcare
Our verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.